Home » Stocks » MYL

Mylan N.V. (MYL)

Nov 17, 2020 - MYL merged into VTRS
Stock Price: $15.86 USD 0.00 (0.00%)
Updated Nov 16, 2020 4:00 PM EST

Stock Price Chart

Key Info

Market Cap 8.59B
Revenue (ttm) 11.51B
Net Income (ttm) 266.40M
Shares Out 541.55M
EPS (ttm) 0.52
PE Ratio 30.50
Forward PE 3.32
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Nov 16, 2020
Last Price $15.86
Previous Close $15.86
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 15.34 - 16.15
Day's Volume 0
52-Week Range 12.75 - 23.11

More Stats

Market Cap 8.59B
Enterprise Value 20.26B
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 541.55M
Float 538.15M
EPS (basic) 0.52
EPS (diluted) 0.52
FCF / Share 3.26
Dividend n/a
Dividend Yield n/a
Earnings Yield 3.28%
FCF Yield 19.59%
Payout Ratio n/a
Shares Short 47.14M
Short Ratio 11.15
Short % of Float 8.76%
Beta 1.47
PE Ratio 30.50
Forward PE 3.32
P/FCF Ratio 5.10
PS Ratio 0.75
PB Ratio 0.67
Revenue 11.51B
Operating Income 942.60M
Net Income 266.40M
Free Cash Flow 1.68B
Net Cash -11.68B
Net Cash / Share -21.56
Gross Margin 39.53%
Operating Margin 8.19%
Profit Margin 2.30%
FCF Margin 14.61%
ROA 3.63%
ROE 2.22%
ROIC 5.80%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (18)

Buy 9
Overweight 2
Hold 7
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$21.73*
(37.01% upside)
Low
16.0
Current: $15.86
High
27.0
Target: 21.73
*Average 12-month price target from 15 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue11,50111,43411,90811,0779,4297,7206,9096,7966,1305,451
Revenue Growth0.58%-3.98%7.5%17.47%22.15%11.73%1.66%10.87%12.46%-
Gross Profit3,8984,0024,7834,6974,2163,5283,0402,9082,5632,217
Operating Income7169061,4376991,4611,3531,1361,1091,005722
Net Income16.80353696480848929624641537345
Shares Outstanding516515535513472374383415431324
Earnings Per Share0.030.681.300.921.702.341.581.521.220.68
EPS Growth-95.59%-47.69%41.3%-45.88%-27.35%48.1%3.95%24.59%79.41%-
Operating Cash Flow1,8042,3422,0652,0472,0091,0151,107949720931
Capital Expenditures-213-252-276-390-363-325-309-289-280-188
Free Cash Flow1,5912,0901,7891,6571,646690797660441744
Cash & Equivalents4763882929991,236226291350375715
Total Debt12,72213,86314,72115,5397,3748,5048,0305,7345,2995,433
Net Cash / Debt-12,247-13,475-14,429-14,541-6,138-8,278-7,739-5,384-4,924-4,718
Assets31,25632,73535,80634,72622,26815,82115,29511,93211,59811,537
Liabilities19,37220,56822,49923,60912,50212,54512,3358,5768,0937,921
Book Value11,88412,16713,30811,1169,7643,2562,9423,3413,4923,602
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mylan N.V.
Country United Kingdom
Employees 35,000
CEO Heather M. Bresch

Stock Information

Ticker Symbol MYL
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: MYL

Description

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd; and Revance Therapeutics, Inc. The company was founded in 1961 and is based in Hatfield, the United Kingdom.